On July 15, Becton, Dickinson, and Company (hereinafter referred to as "BD"), a global leading medical technology Company, and Hipro Biotechnology Co., Ltd (hereinafter referred to as "Hipro") signed a strategic cooperation agreement in Suzhou. The two parties will establish a new strategic partnership in the field of in vitro diagnostic infection expertise market.
In this cooperation, both parties will start with the inflammatory factor detection project, and through the integration of Hipro patented integrated sampler platform and BD's professional product portfolio in the field of bloodstream infection diagnosis, they are committed to bringing rapid stratified diagnosis solutions for bloodstream infection to Chinese doctors and patients. It is reported that this cooperation is the first national strategic cooperation between BD Medical Integrated Diagnostic Solutions Division and a domestic company, and the first cooperation between a domestic IVD enterprise and a multinational giant in the field of instruments.
Hao Shushun, Chairman of Hipro Biotechnology Co., Ltd., and Wang Xiaoyong, Vice President of BD Greater China Integrated Diagnostics Business Unit, signed the strategic cooperation agreement
At the signing ceremony, Mr. Hao Shushun, Chairman of Hipro Biotechnology Co., Ltd., and Mr. Wang Xiaoyong, Vice President of BD Greater China Integrated Diagnostics Division signed the strategic cooperation agreement on behalf of both parties.
Many of the directions and ideas of Hipro and BD Medical Diagnostics are highly aligned. After BD signs the agreement with HIPRO, both parties will cooperate through product integration, sharing sales and service networks, and other forms. By combining with BD's nosocomial infection products, Hipro’s immunodiagnostic products for infection will open up the product line for in vitro diagnosis. In addition, BD and Hipro can further integrate the R&D technology market and channel resources of both sides to achieve win-win cooperation, innovation, and development.
Starting from the cooperation of PCT, Hipro and BD will leverage their respective advantages to further promote strategic cooperation in the future.
Through the establishment of a good cooperative communication mechanism and the further exploration of the cooperation mode and space, both parties can jointly provide more comprehensive and high-quality testing items in the clinical field, as well as provide more professional and better services for customers.